Hualan Biological Vaccine Inc. (SHE: 301207)
China
· Delayed Price · Currency is CNY 19.75
-0.33 (-1.64%)
Oct 10, 2024, 3:04 PM CST
Hualan Biological Vaccine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Net Income | 777.02 | 859.97 | 519.63 | 620.97 | 924.91 | 375.3 | Upgrade
|
| Depreciation & Amortization | 139.74 | 140.33 | 135.43 | 68.93 | 40.85 | 332.81 | Upgrade
|
| Other Amortization | 2.31 | 4.53 | 6.15 | 1.55 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.51 | 0.45 | -0.58 | 1 | 0.33 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -105.88 | -110.17 | -72.45 | -38.01 | -9.91 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 7.38 | 21.33 | 28.77 | 1.04 | 43.47 | - | Upgrade
|
| Other Operating Activities | 100.65 | 101.28 | 162.54 | 146.32 | 35.02 | -433.06 | Upgrade
|
| Change in Accounts Receivable | -195.66 | -224.19 | -380.76 | 89.38 | -906.3 | - | Upgrade
|
| Change in Inventory | -48.17 | -101.23 | -211.49 | -195.39 | -20.17 | - | Upgrade
|
| Change in Accounts Payable | 59.79 | 170.28 | 117.16 | -116.66 | 669.17 | - | Upgrade
|
| Change in Other Net Operating Assets | 24.32 | 26.04 | 5.98 | 0.48 | 0.06 | - | Upgrade
|
| Operating Cash Flow | 749.18 | 888.02 | 288.66 | 569.33 | 693.71 | 275.04 | Upgrade
|
| Operating Cash Flow Growth | 2.40% | 207.63% | -49.30% | -17.93% | 152.22% | 191.18% | Upgrade
|
| Capital Expenditures | -61.62 | -62.6 | -92.65 | -636.06 | -532.28 | -143.89 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.14 | 0.09 | 0.31 | - | 0 | - | Upgrade
|
| Investment in Securities | 112.67 | -711.21 | -1,712 | -479 | -233.76 | -7.24 | Upgrade
|
| Other Investing Activities | 87.7 | 52.6 | 48.37 | 23.19 | 12.72 | 10.62 | Upgrade
|
| Investing Cash Flow | 138.89 | -721.11 | -1,756 | -1,092 | -753.33 | -140.52 | Upgrade
|
| Short-Term Debt Issued | - | 300 | 300 | 800 | 250 | - | Upgrade
|
| Total Debt Issued | - | 300 | 300 | 800 | 250 | - | Upgrade
|
| Short-Term Debt Repaid | - | -300 | -500 | -500 | -50 | - | Upgrade
|
| Long-Term Debt Repaid | - | - | -1.08 | -1.1 | - | - | Upgrade
|
| Total Debt Repaid | - | -300 | -501.08 | -501.1 | -50 | - | Upgrade
|
| Net Debt Issued (Repaid) | - | - | -201.08 | 298.9 | 200 | - | Upgrade
|
| Issuance of Common Stock | 16.28 | - | 2,276 | - | - | - | Upgrade
|
| Common Dividends Paid | -340.59 | -126.09 | -90.88 | -12.77 | -4.59 | - | Upgrade
|
| Other Financing Activities | 3.15 | - | -31.57 | - | -59.72 | - | Upgrade
|
| Financing Cash Flow | -359.91 | -126.09 | 1,952 | 286.13 | 135.69 | - | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.07 | 0.11 | - | - | - | - | Upgrade
|
| Net Cash Flow | 528.23 | 40.94 | 485.25 | -236.4 | 76.08 | 134.53 | Upgrade
|
| Free Cash Flow | 687.56 | 825.42 | 196.01 | -66.73 | 161.43 | 131.15 | Upgrade
|
| Free Cash Flow Growth | 3.02% | 321.10% | - | - | 23.09% | 313.87% | Upgrade
|
| Free Cash Flow Margin | 29.94% | 34.24% | 10.74% | -3.65% | 6.65% | 12.50% | Upgrade
|
| Free Cash Flow Per Share | 1.14 | 1.37 | 0.33 | -0.12 | 0.30 | 0.24 | Upgrade
|
| Cash Income Tax Paid | 224.86 | 192.05 | 172.31 | 296.12 | 196.8 | 135.79 | Upgrade
|
| Levered Free Cash Flow | 467.73 | 207.95 | -48.25 | -209.35 | 51.01 | 370.74 | Upgrade
|
| Unlevered Free Cash Flow | 471.47 | 211.75 | -41.57 | -201.03 | 52.26 | 370.74 | Upgrade
|
| Change in Net Working Capital | 88.18 | 421.75 | 405.56 | 55.63 | 115.53 | 75.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.